Danaher Co. (NYSE:DHR – Get Free Report) announced a quarterly dividend on Tuesday, December 10th,RTT News reports. Shareholders of record on Friday, December 27th will be paid a dividend of 0.27 per share by the conglomerate on Friday, January 31st. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date of this dividend is Friday, December 27th.
Danaher has raised its dividend payment by an average of 13.4% annually over the last three years. Danaher has a payout ratio of 12.9% indicating that its dividend is sufficiently covered by earnings. Analysts expect Danaher to earn $8.38 per share next year, which means the company should continue to be able to cover its $1.08 annual dividend with an expected future payout ratio of 12.9%.
Danaher Price Performance
Shares of NYSE:DHR opened at $235.44 on Thursday. The firm has a market cap of $170.05 billion, a price-to-earnings ratio of 44.93, a P/E/G ratio of 4.23 and a beta of 0.83. Danaher has a 1 year low of $218.48 and a 1 year high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $249.11 and a 200 day simple moving average of $257.94.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on DHR shares. TD Cowen upped their price objective on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus raised their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Raymond James decreased their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Stephens restated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Finally, Robert W. Baird decreased their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.
Check Out Our Latest Analysis on Danaher
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 2 Robotic Surgery Stocks Challenging Intuitive Surgical’s Lead
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 of the Best Thematic ETFs for Investors in 2025
- Buy P&G Now, Before It Sets A New All-Time High
- The Great CPU Race: AMD and Intel Battle for Dominance
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.